Physician profile
Gregory E Cali
NPI 1043217136
$4,689.08
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $581 · 2021: $347 · 2022: $619 · 2023: $486 · 2024: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.53 |
| Education | $137.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,043.77 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $839.42 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.63 | 2019-2024 | Ofev |
| Grifols USA, LLC | $334.25 | 2019-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $241.38 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $205.03 | 2019-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $188.64 | 2020-2023 | |
| Philips North America LLC | $158.27 | 2019-2024 | (Ak6) Vest Therapy |
| United Therapeutics Corporation | $157.48 | 2019-2023 | Tyvaso, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $149.37 | 2020-2024 | Aralast, Cuvitru |
| Sanofi-Aventis U.S. LLC | $137.98 | 2023-2024 | |
| Genentech USA, INC. | $134.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $130.75 | 2019-2020 | |
| Intuitive Surgical, INC. | $128.29 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $104.85 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $92.38 | 2019-2024 | Hizentra |
| Merck Sharp & Dohme LLC | $44.56 | 2024 | Keytruda |
| Axsome Therapeutics, INC. | $44.53 | 2024 | Sunosi |
| Mallinckrodt Enterprises LLC | $31.58 | 2019 | |
| Pfizer INC. | $29.73 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $18.45 | 2024 | Nuzyra |
| Shire North American Group INC | $18.00 | 2019 | |
| Circassia INC. | $18.00 | 2019 | |
| Janssen Biotech, INC. | $17.76 | 2019 | |
| Amgen INC. | $17.41 | 2024 | Tezspire |
| Vifor Pharma, INC. | $14.87 | 2024 | Zemaira |
| Jazz Pharmaceuticals INC. | $13.25 | 2019 | |
| Mylan Specialty L.P. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.